Published online before print July 23, 2007, doi: 10.1161/CIRCULATIONAHA.106.669101
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;116:737-744.)
© 2007 American Heart Association, Inc.
Heart Failure |
Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes
From the Department of Cardiology (G.H.G., S.Z.A., P.B., R.S.), Gentofte University Hospital, Hellerup; the National Institute of Public Health (G.H.G., J.N.R., S.Z.A., T.K.S., P.B., S.R.), Copenhagen; the Department of Cardiovascular Medicine (T.K.S., M.L.H., F.F., C.T.-P.), Bispebjerg University Hospital, Copenhagen; the Department of Medicine (N.G.), Roskilde County Hospital, Køge; the Department of Cardiology (L.K.), Rigshospitalet, Copenhagen University Hospital, Copenhagen; and the Institute of Public Health Research (M.M.), University of Copenhagen, Copenhagen, Denmark.
Correspondence to Dr Gunnar H. Gislason, Senior Resident, Department of Cardiology, Gentofte University Hospital, Niels Andersens Vej 65, 2900 Hellerup, Denmark. E-mail gg{at}heart.dk
Received December 4, 2006; accepted May 29, 2007.
Background— Undertreatment with recommended pharmacotherapy is a common problem in heart failure and may influence prognosis. We studied initiation and persistence of evidence-based pharmacotherapy in 107 092 patients discharged after first hospitalization for heart failure in Denmark from 1995 to 2004.
Methods and Results— Prescriptions of dispensed medication and mortality were identified by an individual-level linkage of nationwide registers. Inclusion was irrespective of left ventricular function. Treatment with renin-angiotensin inhibitors (eg, angiotensin-converting enzyme inhibitors and angiotensin-2 receptor blockers), β-blockers, spironolactone, and statins was initiated in 43%, 27%, 19%, and 19% of patients, respectively. Patients who did not initiate treatment within 90 days of discharge had a low probability of later treatment initiation. Treatment dosages were in general only 50% of target dosages and were not increased during long-term treatment. Short breaks in therapy were common, but most patients reinitiated treatment. Five years after initiation of treatment, 79% patients were still on renin-angiotensin inhibitors, 65% on β-blockers, 56% on spironolactone, and 83% on statins. Notably, multiple drug treatment and increased severity of heart failure was associated with persistence of treatment. Nonpersistence with renin-angiotensin inhibitors, β-blockers, and statins was associated with increased mortality with hazard ratios for death of 1.37 (95% CI, 1.31 to 1.42), 1.25 (95% CI, 1.19 to 1.32), 1.88 (95% CI, 1.67 to 2.12), respectively.
Conclusions— Persistence of treatment was high once medication was started, but treatment dosages were below recommended dosages. Increased severity of heart failure or increased number of concomitant medications did not worsen persistence, but nonpersistence identified a high-risk population of patients who required special attention. A focused effort on early treatment initiation, appropriate dosages, and persistence with the regimen is likely to provide long-term benefit.
CLINICAL PERSPECTIVE
This article has been cited by other articles:
 |
|
 |
|
  E. L. Fosbol, G. H. Gislason, H. E. Poulsen, M. L. Hansen, F. Folke, T. K. Schramm, J. B. Olesen, D.-M. Bretler, S. Z. Abildstrom, R. Sorensen, et al. Prognosis in Heart Failure and the Value of {beta}-Blockers Are Altered by the Use of Antidepressants and Depend on the Type of Antidepressants Used Circ Heart Fail, November 1, 2009; 2(6): 582 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. B. Granger, I. Ekman, C. B. Granger, J. Ostergren, B. Olofsson, E. Michelson, J. J.V. McMurray, S. Yusuf, M. A. Pfeffer, and K. Swedberg Adherence to medication according to sex and age in the CHARM programme Eur J Heart Fail, November 1, 2009; 11(11): 1092 - 1098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Mazzaglia, E. Ambrosioni, M. Alacqua, A. Filippi, E. Sessa, V. Immordino, C. Borghi, O. Brignoli, A. P. Caputi, C. Cricelli, et al. Adherence to Antihypertensive Medications and Cardiovascular Morbidity Among Newly Diagnosed Hypertensive Patients Circulation, October 20, 2009; 120(16): 1598 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Thanassoulis, I. Karp, K. Humphries, J. V. Tu, M. J. Eisenberg, and L. Pilote Impact of Restrictive Prescription Plans on Heart Failure Medication Use Circ Cardiovasc Qual Outcomes, September 1, 2009; 2(5): 484 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Ho, C. L. Bryson, and J. S. Rumsfeld Medication Adherence: Its Importance in Cardiovascular Outcomes Circulation, June 16, 2009; 119(23): 3028 - 3035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Lamb, D. T. Eurich, F. A. McAlister, R. T. Tsuyuki, W. M. Semchuk, T. W. Wilson, and D. F. Blackburn Changes in Adherence to Evidence-Based Medications in the First Year After Initial Hospitalization for Heart Failure: Observational Cohort Study From 1994 to 2003 Circ Cardiovasc Qual Outcomes, May 1, 2009; 2(3): 228 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): e1 - e90. [Full Text] [PDF]
|
|
|
|
|
|
M. Jessup, W. T. Abraham, D. E. Casey, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. A. Konstam, D. M. Mancini, P. S. Rahko, M. A. Silver, et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1343 - 1382. [Full Text] [PDF]
|
|
|
|
|
|
2009 WRITING GROUP TO REVIEW NEW EVIDENCE AND UPDA, M. Jessup, W. T. Abraham, D. E. Casey, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. A. Konstam, D. M. Mancini, P. S. Rahko, et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): 1977 - 2016. [Full Text] [PDF]
|
|
|
|
|
|
2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): e391 - e479. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Komajda, O. Hanon, M. Hochadel, J. L. Lopez-Sendon, F. Follath, P. Ponikowski, V.-P. Harjola, H. Drexler, K. Dickstein, L. Tavazzi, et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II Eur. Heart J., February 2, 2009; 30(4): 478 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Gislason, J. N. Rasmussen, S. Z. Abildstrom, T. K. Schramm, M. L. Hansen, E. L. Fosbol, R. Sorensen, F. Folke, P. Buch, N. Gadsboll, et al. Increased Mortality and Cardiovascular Morbidity Associated With Use of Nonsteroidal Anti-inflammatory Drugs in Chronic Heart Failure Arch Intern Med, January 26, 2009; 169(2): 141 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Persistence of Pharmacotherapy and Outcomes in Heart Failure Journal Watch Cardiology, September 12, 2007; 2007(912): 4 - 4. [Full Text]
|
|
|
|
|
|
I. Ekman and K. Swedberg Patients' Persistence of Evidence-Based Treatment of Chronic Heart Failure: A Treatment Paradox Circulation, August 14, 2007; 116(7): 693 - 695. [Full Text] [PDF]
|
|